〔Abstract〕 Objective To analyze the clinical efficacy of Shexiang Baoxin Pill combined with lipid-lowering drugs in the treatment of coronary heart disease. Methods A total of 214 patients with coronary heart disease who were treated in Luoyang Yiluo Hospital from May 2019 to May 2021 were selected and divided into an observation group and a control group according to random number table method, with 107 patients in each group. The control group was treated with fenofibrate and rosuvastatin,while the observation group was treated with Shexiang Baoxin Pill on the basis of the control group. The changes of blood lipid indicators, inflammation indicators, and liver and kidney function were compared between the two groups before and after treatment. Results After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein–cholesterol (LDL-C) in the both groups were lower than those before treatment, while the level of high density lipoprotein–cholesterol (HDL-C) was higher than that before treatment, the levels of TC, TG and LDL-C in the observation group were lower than those in the control group, and the level of HDL-C in the observation group was higher than that in the control group, the differences were statistically significant (P < 0.05). The levels of inflammatory factors in the both groups were significantly lower than those before treatment, and the levels of inflammatory factors in the observation group were significantly lower than those in the control group , the differences were statistically significant (P < 0.05). There was no significant difference in the levels of liver and kidney function between the two groups before and after treatment (P > 0.05). Conclusion Shexiang Baoxin Pill combined with lipid-lowering drugs can effectively improve the abnormal metabolism of blood lipids and reduce the inflammatory reaction in patients with coronary heart disease, with high safety.